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ABSTRACT 
PLASMABLAST FREQUENCY AND TRAFFICKING RECEPTOR EXPRESSION 
ARE ALTERED IN PEDIATRIC ULCERATIVE COLITIS 
by Nicole J. Tarlton 
 The incidence of pediatric ulcerative colitis (UC), a chronic autoinflammatory 
disease of the colon, is on the rise.  Although an increased infiltration of B cells from the 
peripheral blood into the colon occurs in UC, B cell trafficking is understudied.  We 
hypothesized that the frequency of circulating plasmablasts (PBs) and their trafficking 
receptor (TR) expression may be indicative of the location and degree of pathology in 
pediatric UC.  We conducted multicolor flow cytometry analyses of circulating IgA+/- 
PBs and IgA+ memory B cells (MBCs) in pediatric UC patients with remission, mild, 
moderate, and severe disease (n=12) and healthy pediatric (n=2) and adult donors (n=11).  
Compared to healthy donors the average frequency of circulating PBs increased 30-fold 
during severe UC activity and positively correlated with Pediatric Ulcerative Colitis 
Activity Index score, C-reactive protein level, and erythrocyte sedimentation rate.  A 
greater percent of PBs in severe patients expressed the gut-homing receptors α4β7 and 
CCR10, and the inflammatory homing molecule P-selectin ligand (P-sel lig).  The percent 
of IgA+ MBCs expressing α4β7, however, was reduced.  Furthermore, expression of the 
small intestine TR CCR9 decreased on α4β7high PBs and on α4β7high/CCR10high PBs and 
MBCs in these patients, consistent with preferential cell targeting to the colon.  In 
conclusion, peripheral blood PBs with a colon-homing phenotype were elevated in 
children with severe UC.  Screening this B cell subset may provide a complementary 
approach in monitoring disease activity or therapeutic efficacy in pediatric UC.
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PREFACE 
 This thesis is composed of three chapters.  Chapter I provides an overview of the 
research project, detailing the rationale behind the project design.  Chapter II presents the 
manuscript entitled Plasmablast Frequency and Trafficking Receptor Expression are 
Altered in Pediatric Ulcerative Colitis in journal format according to the guidelines set 
by the journal Inflammatory Bowel Diseases, to which this manuscript was accepted for 
publication.  Chapter III summarizes the conclusions of this work, as well as discusses 
the future directions for this project. 
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CHAPTER I 
INTRODUCTION 
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Overview of the Research Project 
 Inflammatory Bowel Disease (IBD) is a group of chronic autoimmune and 
inflammatory disorders of the gastrointestinal tract (GI), encompassing Crohn’s Disease 
(CD) and ulcerative colitis (UC).  The two diseases are distinguished based on the 
appearance and location of lesion formation in the GI tract: CD is characterized by 
discreet penetrating lesions that may be spread all throughout the GI tract, while the 
lesions in UC are diffuse and superficial, and only occur in the colon. UC was the initial 
focus of this research because lesion involvement is limited to one organ—the colon—
and hence changes in the parameters we measured could more easily be attributed to 
immunopathology in the colon, vs. in CD where the occurrence of immunopathology in 
one or more organs would have to be accounted for.  
 While both children and adults may be affected by UC, pediatric patients were the 
focus of our study for several reasons: 1) pediatric patients with a recent onset of illness 
(vs. adults that have had the disease for a longer period of time) would demonstrate fewer 
confounding effects of comorbidities and long-term medication, 2) fatal γδ-T cell and 
plasmablast lymphomas have been reported in pediatric patients with IBD, and 3) 
pediatric patients with UC are much understudied in comparison to their adult 
counterparts.   
 While the etiology and mechanism of UC is not fully understood, immunologic 
abnormalities play a role in this disease.  An increased recruitment of lymphocytes from 
the peripheral blood into the colon is one such abnormality, ultimately leading to 
inflammation and GI tissue damage.  The recruitment of circulating lymphocytes, i.e. B 
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and T cells, is tightly controlled by a multi-step process involving trafficking receptors 
(TRs) expressed on the lymphocyte surface, that act in combination to govern these 
immune cells’ migration to the target organ.  Focusing on B cells—a lymphocyte subset 
highly implicated in autoimmune/autoinflammatory disorders such as UC—we 
hypothesized that the percent of circulating plasmablasts (an activated B cell population) 
would be increased during disease activity in pediatric UC and would demonstrate an 
altered pattern of TR expression indicative of cell homing to the colon.  
 We used multicolor flow cytometry analysis to examine the combinatorial 
expression of TRs on the B cell surface.  Our approach is novel in that we examine 10+ 
surface molecules simultaneously using only one tube of cells.  In addition, our protocol 
was designed to require only one tube of peripheral blood from the pediatric donors, 
making participation in this study minimally invasive to the patients.  
 Our research was designed to address the following issues: 1) the methods to 
monitor the progression of disease and the immune response to therapeutics are typically 
invasive, and 2) there remains a need to more effectively follow changes in the immune 
system—which may occur as a natural progression of the disease itself or may result 
from disease treatment—that may lead to severe side effects, such as lymphomas.  We 
have found that pediatric UC patients with severe disease have an increased frequency of 
plasmablasts in the peripheral blood that express α4β7, CCR10, and P-selectin ligand—
TRs which, in combination, are indicative of cell homing to the colon.  Screening this B 
cell subset may provide a complementary approach in monitoring disease activity or 
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therapeutic efficacy, and may provide a target for therapeutics in the treatment of 
pediatric UC. 
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CHAPTER II 
PLASMABLAST FREQUENCY AND TRAFFICKING RECEPTOR EXPRESSION 
ARE ALTERED IN PEDIATRIC ULCERATIVE COLITIS  
 
 
 
 
This is the pre-peer-reviewed version of the following article, “Tarlton, N. J., Green, C. 
M., Lazarus, N. H., Rott, L., Wong, A. P., Abramson, O. N., Bremer, M., Butcher, E. C. 
and Abramson, T. (2012), Plasmablast frequency and trafficking receptor expression are 
altered in pediatric ulcerative colitis. Inflamm Bowel Dis. doi: 10.1002/ibd.22962,” 
which has been published online for early view prior to inclusion in the journal at 
http://onlinelibrary.wiley.com/doi/10.1002/ibd.22962/full.  
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ABSTRACT 
Background: The incidence of pediatric ulcerative colitis (UC), a chronic 
autoinflammatory disease of the colon, is on the rise.  Although an increased infiltration 
of B cells from the peripheral blood into the colon occurs in UC, B cell trafficking is 
understudied.  We hypothesized that the frequency of circulating plasmablasts (PBs) and 
their trafficking receptor (TR) expression may be indicative of the location and degree of 
pathology in pediatric UC.  Methods: We conducted multicolor flow cytometry analyses 
of circulating IgA+/- PBs and IgA+ memory B cells (MBCs) in pediatric UC patients with 
remission, mild, moderate, and severe disease (n=12) and healthy pediatric (n=2) and 
adult donors (n=11).  Results: Compared to healthy donors the average frequency of PBs 
among total peripheral blood lymphocytes increased 30-fold during severe UC activity 
and positively correlated with Pediatric Ulcerative Colitis Activity Index score, C-
reactive protein level, and erythrocyte sedimentation rate.  A greater percent of PBs in 
severe patients expressed the gut-homing receptors α4β7 and CCR10, and the 
inflammatory homing molecule P-selectin ligand (P-sel lig).  The percent of IgA+ MBCs 
expressing α4β7, however, was reduced.  Furthermore, expression of the small intestine 
TR CCR9 decreased on α4β7high PBs and on α4β7high/CCR10high PBs and MBCs in these 
patients, consistent with preferential cell targeting to the colon.  Conclusions: Peripheral 
blood PBs with a colon-homing phenotype (α4β7/CCR10/P-sel lig) were elevated in 
children with severe UC.  Screening this B cell subset may provide a complementary 
approach in monitoring disease activity or therapeutic efficacy in pediatric UC. 
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mouse serum; PB, plasmablast; PBMC, peripheral blood mononuclear cell; P-sel lig, P-
selectin ligand; PUCAI, Pediatric Ulcerative Colitis Activity Index; SLE, systemic lupus 
erythematosus; TR, trafficking receptor; UC, ulcerative colitis. 	  
INTRODUCTION 
 Inflammatory Bowel Disease (IBD) is a group of chronic autoinflammatory 
disorders of the gastrointestinal tract, characterized by lesions in the intestinal mucosa.  
While the precise etiology of IBD remains unclear, it is apparent that a genetic 
predisposition coupled with environmental triggers leads to an abnormal immunologic 
response in the gut1.  Ulcerative colitis (UC) is an IBD typified by diffuse lesions spread 
throughout the colon2.  Although the onset of UC may occur in either childhood or 
adulthood, pediatric patients often present with a more extensive disease at diagnosis3.  
Furthermore, the incidence of pediatric UC has risen globally4, as well as in Northern 
California5, the location of our study. 
 Intestinal homeostatic conditions are altered in UC, and antibody-secreting cells 
(ASCs) are implicated in this immunopathology6,7.  There is an increased infiltration of 
immature proliferative plasma cells in ulcer bases8 and an increased level of IgA and IgG 
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ASCs in the colonic mucosa of active UC patients9,10.  Furthermore, autoantibody 
production is detected in UC; IgG ASCs from the peripheral blood and colon of UC 
patients secrete anti-colon antibodies11.  In patients with inactive disease, increased 
numbers of ASCs in the colonic lamina propria is a predictive factor of relapse12. 
 While it is clear that B cells contribute to UC, the mechanism controlling their 
migration to the affected tissue is not fully understood and is especially understudied in 
pediatric UC.  Under homeostatic conditions, B cells circulate through lymphoid tissues 
to develop and sustain an immune defense.  Their recirculation is tightly controlled by the 
sequential association of adhesion molecules with integrin receptors and chemo-attractant 
“trafficking receptors” (TRs) expressed on the B cell surface13.  Unique combinations of 
TRs direct circulating B cells to specific tissues14.  For instance many IgA+ ASCs express 
TRs that can direct their homing to the intestines, including α4β7, an integrin receptor for 
the mucosal vascular addressin MAdCAM-115, and CCR9 and/or CCR10, 
chemoattractant receptors for the small intestine chemokine CCL25 and the common 
mucosal chemokine CCL28, which is highly expressed in the colon14,16,17.   
 Peripheral blood plasmablasts are proliferating, immature precursors of tissue 
plasma cells, and thus may be indicative of disease activity in the colon of UC patients.  
While healthy adults and children maintain low levels of PBs in the peripheral blood18,19, 
these levels rise during natural infection20, after vaccination21, in bacterial septicemia and 
liver cirrhosis22, in children and adults with active systemic lupus erythematosus 
(SLE)19,22, and in adults with active IBD23.  In this study we hypothesize that the 
percentage and TR phenotype of peripheral blood PBs will reflect the disease severity 
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and location of pathology in pediatric UC.  Thus, we compared the frequency of 
peripheral blood B cell subsets and their associated TR expression in UC patients with 
different disease activity and healthy donors.  Through multicolor flow cytometry 
analysis we show an increased percent of IgA+/- PBs expressing α4β7, CCR10, and P-
selectin binding epitopes in the peripheral blood of children with severe UC.  This TR 
phenotype may be indicative of the mechanism of migration of these cells to the inflamed 
colon.  
 
ETHICAL CONSIDERATIONS 
 This study was performed with IRB approval from Kaiser Permanente (IRB# CN-
09AWong-01-H) and San José State University (IRB# S0902237).  All blood samples 
used in this study were obtained with informed consent. 
 
MATERIALS AND METHODS 
Experimental design and subjects 
 Pediatric UC patients were enrolled in this study by pediatric gastroenterologists 
at Kaiser Permanente in Northern California, who used clinical lab tests, 
endoscopy/colonoscopy, histopathology, and radiology findings to establish a diagnosis 
of UC.  Disease activity was assessed using the Pediatric Ulcerative Colitis Activity 
Index (PUCAI)24, and patients were grouped according to disease severity for analysis 
(Table 1).  Peripheral blood samples were obtained from the patients during routine 
blood-work or prior to anti-TNF-α infusion therapy.  Twelve pediatric UC patients 
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participated in this study.  A second sample was obtained from five patients during a 
different severity of disease and/or at a different time point than their first donation, for a 
total of seventeen peripheral blood patient samples processed for this study.  There were 
six female and six male patients, ranging from 8-16 years of age (mean of 13).  Samples 
were grouped for analysis according to the patient’s disease severity at the time of the 
blood draw, as outlined in Table 1. 
£ Activity group is based on PUCAI user guide (score range from 0-85): Remission, <10; 
Mild, 10-34; Moderate, 35-64; Severe, ≥65. 
¥ The remission group was excluded from most analyses due to the small sample size, 
which precluded the use of statistical analyses on this patient as a group.  
*Anti-inflammatory agents: 5ASA and steroids. 
**Immunomodulators: Imuran, Methotrexate, and 6MP. 
***Biological therapies: anti-TNF-α monoclonal antibodies, Humira and Remicade. 
ξ, §, †, δ, ‡ Samples with the same symbol were obtained from the same patient.  
M male, F female, ESR erythrocyte sedimentation rate, CRP C-reactive protein, 5ASA 5-
aminosalicylic acid, 6MP 6-mercaptopurine. 
 
 
Sample
PUCAI 
score (0-85)
£PUCAI disease 
activity group Age (years)
Gender 
(M/F) ESR CRP Treatment
1 0 ¥Remission 12 M 9 0.2 **Methotrexate
ξ2 10 Mild 16 M 3 0.1 ***Remicade
3 10 Mild 9 F 33 0.1 **Imuran, *5ASA
4 15 Mild 16 M 51 1.6 ***Humira
§5 20 Mild 8 M 13 0 *Steroids
ξ6 20 Mild 16 M 8 0.1 ***Remicade
7 25 Mild 15 F 35 0 ***Remicade, 
**Imuran
8 30 Mild 15 F 24 0.1 *Steroids
9 35 Moderate 15 F 31 0 *5ASA
10 50 Moderate 15 F 13 0.2
*5ASA, *Steroids, 
and **6MP before 
***Remicade
†11 60 Moderate 9 M 40 0.8 ***Humira
†12 65 Severe 9 M 39 0.8 ***Humira 
δ13 65 Severe 15 M 29 3.7 ***Remicade
§14 75 Severe 8 M 87 2.3 *Steroids
‡15 75 Severe 15 F 48 4.2 ***Remicade
δ16 75 Severe 15 M 85 6.9 ***Remicade
‡17 75 Severe 15 F 71 3.9 ***Remicade
TABLE 1.     List of pediatric UC patients and sample information
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 Healthy donors were selected for this study based on lack of IBD disease as well 
as any other illness (gastrointestinal, respiratory, etc.) for at least one month prior to 
blood collection.  A total of thirteen different healthy donors (two pediatric and eleven 
adult) participated in this study—ten female and three male—ranging from 15-47 years 
of age (mean of 32).  One sample per healthy donor was used.  
  
Lymphocyte separation from whole blood  
 Heparinized peripheral blood samples were obtained via venipuncture from the 
different donor populations: 10 ml from pediatric UC patients (n=17) and 20 ml from 
healthy donors (n=13).  Blood samples were processed using Ficoll (Histopaque-1077, 
Sigma-Aldrich, St. Louis, MO) density gradient centrifugation, and the peripheral blood 
mononuclear cell (PBMC) layer was extracted.  PBMCs were washed twice in HBSS 
without Ca++/Mg++, and were resuspended in staining buffer (1X PBS with 2% FCS and 
0.1% sodium azide).  Cells were blocked overnight with normal human serum (H4522, 
Sigma-Aldrich) and normal goat serum (Gibco, Invitrogen by Life Technologies, 
Carlsbad, CA), and cells were then stained and acquired. 
 
Monoclonal antibodies for flow cytometry phenotypic analysis 
 Primary conjugated antibodies: mouse anti-human CD38 PE-Cy7 (Clone HB7, 
BD Biosciences, San Jose, CA), goat F(ab’)2  anti-human IgA FITC (Invitrogen), mouse 
anti-human CD19 Alexa Fluor 700 (Clone HIB19, BD Biosciences), rat anti-human  
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CD49f PE-Cy5 (Clone GoH3, BD Biosciences), and mouse anti-human CD4 V500 
(Clone RPA-T4, BD Biosciences).  
 Primary unconjugated antibodies: mouse anti-human CCR9 (ATCC, Manassas, 
VA) and anti-human CCR10 (courtesy Dr. Dulce Soler-Ferran, Millennium 
Pharmaceuticals, Cambridge, MA) were labeled in-house using goat F(ab’)2 anti-mouse 
Pacific Blue (Invitrogen) and goat F(ab’)2  anti-mouse Qdot655 (Invitrogen), respectively.  
Mouse anti-human α4β7 (Act-1, ATCC) was PE conjugated by Chromoprobe (St. Louis, 
MO).  Recombinant human P-selectin Fc chimera (R&D Systems, Minneapolis, MN) was 
labeled in-house with the Zenon Alexa Fluor 647 human IgG labeling kit (Invitrogen).  
Biotin rat anti-human CLA (cutaneous lymphocyte antigen, Clone HECA-452, BD 
Biosciences) was labeled in-house with Streptavidin Qdot565 (Invitrogen).  
 
Cell staining and flow cytometry analysis  
 PBMCs (3x106 per donor sample) were stained with the previously mentioned 
antibodies.  First, cells were stained with primary anti-CCR9 antibody, washed, and 
labeled with secondary anti-mouse Pacific Blue.  After a second wash, cells were blocked 
with normal mouse serum (NMS, Santa Cruz Biotechnology, Santa Cruz, CA).  Next 
primary anti-CCR10 antibody was labeled with secondary anti-mouse Qdot655 and was 
then added to the cells.  A bench-top conjugation with P-selectin and Zenon AF647 was 
performed, and the conjugate was added to the cells to stain P-selectin ligand (P-sel lig).  
A cocktail of the primary conjugated antibodies was then applied to the cells.  
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Subsequently, cells were stained with primary anti-CLA biotin antibody, washed, and 
labeled with Streptavidin Qdot565.  Then a final wash was performed.  
 Alongside the donor sample, an isotype control with 3x106 PBMCs was prepared 
for the four primary antibodies labeled in-house, using the second stage alone of n-1 
(addition of Pacific Blue without CCR9, Qdot655 without CCR10, and Qdot565 without 
CLA), and an incubation of the cells with 0.5M EDTA (to interrupt the binding of P-sel 
with P-sel lig).  In addition, 10% NMS was added in place of the primary antibodies 
CCR9, CCR10, and CLA.  Apart from these modifications, the isotype control was 
prepared in the same manner as the donor sample.  All samples were acquired on a BD 
Biosciences LSRII flow cytometer (in the Butcher lab at Stanford University) using 
FACSDiva software.   
 Flow cytometry data were analyzed using FlowJo software (Tree Star Inc., 
Ashland, OR).  TR gates were placed based on the isotype controls or a bimodal 
comparison of the positive and negative staining populations.  During data analysis, 
positive staining in the isotype control for CCR9, CCR10, P-sel lig, and CLA was 
subtracted from the donor sample value to account for non-specific binding.  
 
Statistical analysis   
 Differences in the percent of IgA+/- PBs and IgA+ MBCs between the pediatric 
(n=2) and adult (n=11) healthy donors were analyzed using the Wilcoxon test.  In 
addition, relationships between the demographic variables of the UC patients (age, 
gender, and drug treatment) and the response variables IgA+ PBs, IgA- PBs, and IgA+ 
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MBCs were investigated.  To determine whether there is a relationship between the age 
of the patient and the response levels, we regressed the responses individually on age and 
tested for zero slope in regression with a regression F-test.  To test whether the gender of 
the patients has an influence on the responses, we used Wilcoxon’s test.  To test whether 
the mean responses of the patients vary by the treatment regimen they are subjected to, 
we performed an analysis of variance (ANOVA F-test).  For this analysis the patients 
were placed into three groups based on treatment: anti-inflammatory agents, 
immunomodulators, and biological therapies (therapies detailed in Table 1).  If the 
patient was treated with multiple therapies the patient was placed in a treatment group 
based on the strongest therapy received (anti-inflammatory agents< immunomodulators< 
biological therapies).  All other statistical analyses were performed using Student’s t-test 
or linear regression analysis, as identified in the Results section.  A p<0.05 value was 
considered statistically significant.    
 
RESULTS 
Peripheral blood B cell subsets in pediatric UC patients 
 Circulating plasmablasts (PBs) are in transit to the tissue, where they mature into 
antibody-secreting cells (ASCs); thus, an increased quantity in the peripheral blood may 
indicate disease activity in the colon of UC patients.  Memory B cells (MBCs) are an 
immunologic surveillance population that reflect past antigen encounter, and comprise a 
pool of cells from which PBs specific to previously encountered antigens may be derived.  
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We monitored the percent of IgA+ PBs, IgA- PBs, and IgA+ MBCs in the peripheral 
blood, to determine whether these B cell subsets were increased in pediatric UC.  
 Three B cell populations were gated from the PBMCs (Figure 1A-C): 
CD38high/IgA- cells (IgA- PBs), CD38high/IgA+ cells (IgA+ PBs), and CD38med/low/IgA+ 
cells (IgA+ MBCs)20.  IgA+ MBCs were further gated to select for CD19 expression.  
CD4+ cells were gated out to exclude them from analysis. There was no difference in the 
frequency of IgA+ PBs between pediatric (0.11%) and adult (0.08%) healthy donors 
(Wilcoxon test, p=0.23), or in the frequency of IgA- PBs (0.05 and 0.08% respectively, 
p=0.92) or IgA+ MBCs (0.47 and 0.62%, p=0.77) (data not shown).  Therefore all healthy 
donors were combined for statistical comparisons.   
 Pediatric UC patients with severe disease had a greater percent of IgA+ PBs 
among total peripheral blood lymphocytes (2.48%) than healthy controls (0.09%, 
p=0.02), as well as patients with mild (0.26%, p=0.02) and moderate (0.16%, p=0.02) 
disease activity (Figure 1D).  While the percent of IgA- PBs was greater in severe UC 
patients (2.54%) compared to other groups, this difference was not statistically significant 
(Figure 1E).  However, when a severe patient who had 7.6% IgA- PBs (a high outlier) 
was removed from the analysis, the percent of IgA- PBs in severe patients (1.5%) was 
greater than that in healthy donors (0.07%, p=0.03), mild (0.23%, p=0.048) and moderate 
(0.18%, p=0.04) UC patients.  In contrast to the PBs, the percent of IgA+ MBCs was 
similar between healthy and UC patient groups (average range from 0.5-1.2%, p>0.05 for 
all comparisons) (Figure 1F).  
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FIGURE 1.  Representative flow cytometry plots of B cell subset gating strategy.  From 
left to right: (A) lymphocytes are gated, (B) three B cell subsets are identified— the IgA- 
plasmablasts (PBs), the IgA+ PBs, and the IgA+ memory B cells (MBCs), then (C) the 
IgA+ MBCs are further gated for CD19 expression.  The percent of (D) IgA+ PBs, (E) 
IgA- PBs, and (F) IgA+ MBCs out of total peripheral blood lymphocytes was determined 
for all healthy donor and pediatric UC patient blood samples.  Samples were grouped 
according to type of donor; groups here are healthy donors (HD) (black dots are pediatric 
HD, and white dots are adult HD), and pediatric patients with mild UC (MILD), 
moderate UC (MOD), and severe UC (SEV) disease activity.  Circles represent individual 
samples and bars represent the group’s average. Student’s t-test was performed between 
all UC patient groups vs. healthy donors, and between the severe group vs. the mild and 
moderate UC groups.  *p<0.05; no asterisk indicates p>0.05.  Significance (p<0.05) is 
present in (E) when the severe patient with the highest percent of IgA- PBs (a high 
outlier) is removed from the analysis.  
 
 Within the UC patients, there was no correlation between age of the patient and 
percent of IgA+ PBs (regression F-test, p=0.93), IgA- PBs (p=0.67), or IgA+ MBCs 
(p=0.31), or between the gender of the patient and the percent of IgA+ PBs (Wilcoxon 
test, p=0.35), IgA- PBs (p=0.92), or IgA+ MBCs (p=0.92) (data not shown).  
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Additionally, no significant difference was observed in the mean percent of IgA+ PBs 
between the patients being treated with anti-inflammatory agents, immunomodulators, or 
biological therapies (ANOVA F-test, p=0.62), or in the percent of IgA- PBs (p=0.72) and 
IgA+ MBCs (p=0.56) (data not shown).  
 
Correlation between circulating plasmablasts and clinical parameters in 
pediatric UC patients 
 Inflammatory activity in pediatric UC patients is closely monitored using clinical 
lab tests such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR).  In 
addition, the PUCAI scoring system is an assessment tool that provides a way to quantify 
UC disease severity based on reported symptoms.  
 Both CRP and ESR values positively correlate with PUCAI score in pediatric UC 
patients (Figure 2) (R=0.72 and R=0.71 respectively).  The percent of peripheral blood 
IgA+ PBs, and to a lesser degree IgA- PBs, correlate with PUCAI score at a comparable 
level to these established clinical tests (R=0.67 and R=0.54 respectively).  In addition, the 
percent of IgA+ PBs in circulation correlates very well with CRP (R=0.89) and with ESR 
(R=0.74), while the percent of IgA- PBs correlates well, but to a lesser extent (with CRP 
R=0.87, and with ESR R=0.62).  Overall, the frequency of IgA+ PBs in the peripheral 
blood correlated well, and better, than the IgA- PBs with each of the tested parameters 
(data not shown for IgA- PBs or ESR).  
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FIGURE 2.  Linear regression analyses in pediatric patients with UC.  (A) Correlation 
between serum C-reactive protein (CRP) levels and PUCAI score.  (B) Correlation 
between percent of IgA+ plasmablasts (PBs) out of total peripheral blood lymphocytes 
and Pediatric Ulcerative Colitis Activity Index (PUCAI) score.  (C) Correlation between 
percent of IgA+ PBs out of total peripheral blood lymphocytes and CRP.  
 
Single trafficking receptor analysis of plasmablasts  
 Previous studies indicate that expression of the TR ligands MAdCAM-1 and 
CCL28, and the vascular receptor P-selectin, is increased in the inflamed colon tissue of 
UC patients25,26,27.  Thus, we determined whether circulating PBs in UC patients 
demonstrated an altered expression of the corresponding TRs, α4β7 and CCR10, and P-
sel lig, respectively.  In addition CCR9 (a TR with particular relevance to small intestine 
homing but not colon homing16,28) was examined.  Since extraintestinal manifestations 
may occur in patients with IBD, we also measured the expression of the skin homing 
receptor CLA29, a carbohydrate ligand for vascular E-selectin, and the integrin α6 chain 
(i.e. CD49f), whose expression is associated with homing to the skin, lung, and other 
extraintestinal sites30,31.  IgA+/- PBs were identified as shown in Figure 1, then TR 
expression was examined using the gating strategy in Figure 3A. 
 Severe UC patients displayed a greater percent of α4β7high IgA+ PBs (69% of IgA+ 
PBs) in circulation than healthy donors (43%, p=0.002) and moderate patients (46%, 
p=0.001) (Figure 3B).  Similarly, the percent of CCR10high IgA+ PBs was increased in  
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FIGURE 3.  Single trafficking receptor (TR) analysis on IgA+/- plasmablasts (PBs).  (A) 
Representative flow cytometry dot plots of individual TR expression on PBs.  Gates 
represent high-TR-expressing cells.  Average percent of (B) IgA+ PBs and (C) IgA- PBs 
with TRhigh expression of α4β7, CCR10, P-selectin ligand (P-sel lig), CCR9, CD49f, or 
CLA.  Student’s t-test was performed between all UC patient groups vs. healthy, and 
between the severe group vs. the mild and moderate UC groups.  *p<0.05, **p<0.01, 
***p<0.001; no asterisk indicates p>0.05.  
	  	  22	  
severe UC patients (56% of IgA+ PBs) compared to healthy donors (12%, p=0.0001), and 
patients with mild (28%, p=0.02) and moderate (26%, p=0.003) disease.  Furthermore, P-
sel lighigh IgA+ PBs were more frequent in severe UC patients (29% of IgA+ PBs) 
compared to healthy donors (18%, p=0.03) and patients with mild disease (15%, p=0.02).  
The IgA- PBs demonstrated similar trends to the IgA+ PBs for all three TRs (Figure 3C).  
 On average UC patients had fewer CCR9high PBs than HDs, and UC patients with 
moderate disease demonstrated significantly less CCR9high IgA+ and IgA- PBs (9 and 4% 
respectively) than healthy donors (18 and 13%, p=0.04 and p=0.048, respectively).  The 
percent of CD49fhigh and CLAhigh PBs was mainly similar between groups. 
 
Trafficking receptor expression on mucosal and non-mucosal 
plasmablasts 
 The combinatorial expression of TRs drives cell homing to the intestines and 
other sites13.  Since we observed an increase in PBs that express CCR10 and P-sel lig in 
severe UC, we further investigated whether this correlated with α4β7 expression and 
whether this TR expression occurred primarily on the mucosal (α4β7high) or non-mucosal 
(α4β7low) homing cells.  IgA+ and IgA- PBs from Figure 1 were segregated into α4β7high 
and α4β7low populations, then analyzed for the expression of other TRs as shown in 
Figure 4A.  
 The percent of mucosal IgA+ PBs with CCR10high and P-sel lighigh expression was 
greater in severe UC patients (59% and 28% respectively) than in healthy controls (15%, 
p=0.0002, and 9%, p=0.001 respectively), and patients with mild (30%, p=0.03, and 13%, 
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p=0.0099) and moderate disease (29%, p=0.004, and 13%, p=0.01) (Figure 4B).  
Although the percent of CCR10high cells was similar in the α4β7high and α4β7low IgA+ PB 
subsets, P-sel lig had a greater percentage of expression in the non-mucosal cells.  Similar 
expression patterns for CCR10 and P-sel lig were observed in the mucosal and non-
mucosal IgA- PBs (Figure 4C).  
 The frequency of mucosal IgA+ PBs with CCR9high expression was decreased in 
moderate (16%, p=0.02) and severe (15%, p=0.002) UC patients compared to healthy 
donors (36%); similar trends were observed in the IgA- PBs.  The percent of CCR9high 
non-mucosal PBs was low in all groups, and on average less than 5% of non-mucosal 
PBs demonstrated CCR9high expression.  The frequency of mucosal IgA+/- PBs with 
CD49f high expression was similar for healthy and UC patient groups (average range 
between 12-20%).  However, α4β7low non-mucosal PBs with CD49f high expression were 
consistently increased (average range between 27-32%) compared to their α4β7high 
mucosal homing counterparts.   
 The cellular expression of α4β7 and CLA are usually mutually exclusive, as these 
TRs mediate lymphocyte homing to different sites.  Therefore the percent of mucosal PBs 
that were CLAhigh was very low—on average less than 6% of cells (CLA data not 
shown). The frequency of CLAhigh cells among non-mucosal PBs was also low—on 
average less than 10% of cells.  
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 FIGURE 4.  Trafficking receptor (TR) analysis on mucosal (α4β7high) and non-mucosal 
(α4β7low) IgA+/- plasmablasts (PBs).  (A) Representative flow cytometry plots for TR 
gating strategy on PBs.  From top to bottom: IgA+/- PBs are gated for α4β7high expression 
(upper gate) and α4β7low expression (lower gate), then individual TR expression is 
examined on each of these subsets.  Gates represent cells with TRhigh expression of 
CCR10, P-selectin ligand, CCR9, or CD49f.  Bar graphs display the average percent of 
α4β7high and α4β7low (B) IgA+ PBs and (C) IgA- PBs with TRhigh expression.  Statistical 
analyses for α4β7high cells were performed between all UC patient groups vs. healthy, and 
between the severe group vs. the mild and moderate UC groups.  In addition, statistical 
analyses were performed between α4β7high and α4β7low cells within groups using 
Student’s t-test.  *p<0.05, **p<0.01, ***p<0.001; no asterisk indicates p>0.05.  
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Trafficking receptor expression on memory B cells 
 MBCs act as an immunological surveillance population, and their presence 
reflects past antigen encounter.  Since UC is a chronic disease, we predicted that TR 
expression on peripheral blood MBCs may be indicative of the location of past disease 
activity in UC patients.  We compared the TR expression of IgA+ MBCs to their activated 
counterparts, the IgA+ PBs, and also compared IgA+ MBC TR expression between donor 
groups. 
 The differential TR expression on IgA+ PBs and MBCs is visually demonstrated 
in overlay dot plots of the two B cell populations from all severe UC patients (Figure 
5A).  Co-expression of α4β7 and CCR10 or P-sel lig was consistently higher on PBs than 
MBCs.  However, the co-expression of α4β7 and CCR9 or CD49f was more similar 
between the cell subsets.  
FIGURE 5.  Comparison of IgA+ plasmablasts (PBs) and 
IgA+ memory B cells (MBCs).  (A) Flow cytometry dot 
plot overlays of trafficking receptor (TR) co-expression 
of α4β7 with CCR10, P-sel lig, CCR9, or CD49f on IgA+ 
PBs (white dots) and IgA+ MBCs (black dots) from all 
severe UC patients combined.  (B) Single TR expression 
on IgA+ MBCs, showing the average percent of MBCs 
with α4β7high expression in each donor group.  Student’s 
t-test was performed between all UC patient groups vs. 
healthy, and between the severe group vs. the mild and moderate UC groups.  **p<0.01; 
no asterisk indicates p>0.05.  
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 Unlike the PBs, the frequency of CCR10high, P-sel lighigh, CCR9high, and CD49fhigh 
IgA+ MBCs was similar in healthy donors and UC patients (p>0.05 for all comparisons; 
data not shown).  However in contrast to the α4β7high PBs, the frequency of α4β7high IgA+ 
MBCs was decreased in severe UC patients (35%) compared to healthy donors (51%, 
p=0.004) (Figure 5B).  
 
CCR9 expression on B cell subsets co-expressing α4β7 and CCR10 
 α4β7 and CCR10 expression without CCR9 is expected to favor cell homing to 
the colon, as MAdCAM-1 and CCL28 are highly expressed in the colon, whereas CCR9 
and its ligand CCL25 are major determinants of lymphocyte recruitment to the small 
intestine14.  Therefore we examined α4β7high/CCR10high B cell subsets for CCR9 
expression.  
 In general the proportion of α4β7high/CCR10high PBs and MBCs expressing CCR9 
decreased as the severity of UC disease intensified (Figure 6).  The frequency of 
α4β7high/CCR10high IgA+ and IgA- PBs with CCR9 expression was decreased in the 
moderate (23%, p=0.04, and 8%, p=0.03 respectively) and severe (17%, p=0.009, and 
12%, p=0.04) UC disease activity groups compared to healthy donors (43 and 33%).  In 
addition, the percent of α4β7high/CCR10high IgA+ MBCs expressing CCR9 in severe UC 
(30%) was decreased compared to healthy controls (50%, p=0.02). 
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FIGURE 6.  CCR9 expression on α4β7high/CCR10high IgA+/- plasmablasts (PBs), and 
IgA+ memory B cells (MBCs).  Samples were grouped according to type of donor: 
healthy donors (HD) and pediatric patients with mild UC (MILD), moderate UC (MOD), 
and severe UC (SEV) disease activity.  Statistical analyses within each B cell subset were 
performed between healthy donors and UC patient disease activity groups using 
Student’s t-test.  *p<0.05; no asterisk indicates p>0.05.  
 
     DISCUSSION 
 B lymphocytes contribute to the immunopathology of UC6,7; however, the 
mechanisms controlling migration to the affected tissue in this disease is understudied.  
We examined peripheral blood B cell subsets in UC patients using the rationale that their 
frequency and migratory potential, reflected by their TR expression, would be altered and 
therefore indicative of B cell activity in the colon.  The purpose of this study was to 
characterize TR expression on B cell subsets, specifically PBs, elicited in UC.  We 
focused our study on pediatric patients with recent onset of illness and hence with fewer 
confounding effects of comorbidities and long-term medication.   
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 Here we showed that the average frequency of both IgA+ and IgA- PBs were 
elevated in children with severe UC as compared to healthy donors and patients with mild 
and moderate disease activity.  Similar findings have recently been reported by Hosomi et 
al.23 in adult UC patients with active disease.  In contrast, the percent of peripheral blood 
IgA+ MBCs was unaltered in patients at all disease activity levels compared to healthy 
individuals—a feature that has been demonstrated in other chronic autoimmune disorders 
such as pediatric SLE19.  Therefore the frequency of peripheral blood PBs, but not MBCs, 
is a good indicator of disease severity and inflammation in UC. 
 As the UC disease activity increased in severity, we observed a dramatic increase 
in the percent of IgA+ and IgA- PBs with α4β7high and CCR10high or P-sel lighigh co-
expression, supporting the hypothesis that these TRs play a role in PB migration to the 
colon in UC.  Of note, Hosomi et al.23 did not observe an increase in CCR10 expressing 
PBs (defined as CD19+/CD20- cells) in adult UC.  Since all activity levels were combined 
in their study, perhaps a rise in CCR10 expressing PBs was masked by UC patients with 
milder disease.  Another possibility is that the relevance of CCR10 is different in adult 
UC vs. pediatric UC, and this TR has greater significance during the initial onset or early 
in disease. 
 P-sel lig, along with its corresponding receptor P-selectin, is upregulated in 
immune cells and on the vascular endothelium in response to inflammation32.  In this 
study we observed an increased frequency of both α4β7low and α4β7high PBs expressing P-
sel lig in severe UC, further indicating the high levels of colon inflammation at this stage 
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of disease and perhaps reflecting the massive migration of cells expressing P-sel lig into 
the inflamed colon. 
 There was a trend in the mild and moderate activity groups for an increased 
percent of α4β7high PBs but not CCR10high and P-sel lighigh cells; only patients with severe 
disease activity displayed a higher frequency of CCR10high and P-sel lighigh PBs.  It is 
possible that UC therapeutics decrease certain TR responses, i.e., CCR10 and P-sel lig 
upregulation on cells.  Alternatively, high CCR10 and high P-sel lig expression may be 
imprinted on PBs only at advanced stages of disease, where intensified exposure to colon 
antigens has occurred due to extensive inflammation and tissue damage.  Thus a rise in 
the frequency of peripheral blood PBs imprinted with high CCR10 and high P-sel lig 
expression may reflect a more acute manifestation of UC than does a rise in PBs with 
high α4β7 only.        
 The frequency of IgA+ MBCs expressing α4β7 at high levels decreased as UC 
disease activity intensified, and severe patients had a lower proportion of these cells 
compared to healthy donors.  α4β7high MBCs may redistribute from the blood to the 
intestines in response to inflammation or may be re-activated in patients during a flare in 
disease activity and thus become depleted from the circulating α4β7 MBC pool.  
 We found a reduced frequency of PBs with CCR9high expression in pediatric UC, 
and moderate and severe patients had fewer PBs co-expressing α4β7 and CCR9.  There is 
no small intestine involvement in UC, a disease that solely affects the colon; therefore no 
upregulation in CCR9, which preferentially targets lymphocytes to the small intestine, 
was expected.  In severe UC patients, there was also a decrease in the percent of 
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α4β7high/CCR10high PBs and MBCs that express CCR9, which indicates these patients 
have increased levels of PBs that may preferentially migrate to the colon vs. the small 
intestine33.  
 Extraintestinal manifestations may occur in pediatric IBD, and some patients 
develop pathologies of the skin, liver and other complications34,35.  The proportion of 
cells that expressed CLA, a trafficking molecule associated with skin homing, was low 
on both PBs and MBCs.  However, only one of the pediatric UC patients in this study 
developed a skin pathology, which may explain the low frequency of cells expressing this 
molecule.  
 While the role of the integrin receptor CD49f (i.e. α6) in UC is not well 
documented, B cells in the colon of UC patients, but not in the colon of Crohn’s or non-
IBD patients, were found to express this receptor36.  In our study the frequency of B cells 
expressing CD49f was unaltered in UC, and the expression of the receptor was more 
prominent on α4β7low cells, supporting the idea that CD49f is not associated with gut-
homing lymphocytes30.  Our results indicate that CD49f plays a minimal role in B cell 
trafficking in pediatric UC.  
 In conclusion, our study demonstrates an increase in the frequency of IgA+ and 
IgA- PBs in the peripheral blood of severe UC patients.  PB frequency positively 
correlates with UC disease severity and inflammation, indicating circulating PB subsets 
as a good indicator of disease activity in pediatric UC.  In addition, circulating IgA+/- PBs 
with α4β7high/CCR10high/P-sel lighigh expression are elevated in pediatric UC patients with 
severe disease.  In combination these trafficking receptors likely facilitate PB homing to 
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the inflamed colonic tissue.  Thus, this cell subset may provide a therapeutic target for the 
treatment of UC, and the surveillance of circulating PBs and their associated TR 
expression may potentially be used as a non-invasive, complementary approach to 
monitor disease activity or therapeutic efficacy in children with this disease.   
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Conclusions 
 Ulcerative colitis (UC) is a serious and life altering disorder for which an 
effective therapeutic regimen can be difficult to establish.  In this work we utilized 
multicolor flow cytometry analysis to determine the relationship between the frequency 
of circulating plasmablasts (PBs) and their associated trafficking receptors (TRs) with the 
severity of disease in the colon in pediatric UC patients.  We show here that the percent 
of peripheral blood PBs with α4β7high/CCR10high/P-sel lighigh expression are indicative of 
the severity of disease and location of pathology in pediatric UC.   
 Our work suggests that circulating PB subsets may provide a useful parameter to 
monitor in the evaluation of pediatric UC patients' progression of disease and response to 
treatment.  Our complementary approach would provide both a relatively non-invasive 
and specific method for monitoring the immune system in these patients.  The PB subsets 
and TRs we have indicated here may also provide a therapeutic target for the treatment of 
UC.  
Future Directions 
 To further investigate the significance of PBs and their associated TR expression 
in Inflammatory Bowel Disease (IBD), we plan to expand our research in the following 
directions: 
 1.  We will expand the panel of TRs examined on PBs to include additional 
trafficking molecules with relevance in inflammation—for instance the chemokine 
receptors CXCR3 and CXCR4. 
 2.  We will examine circulating PB subsets in pediatric Crohn's Disease (CD) 
	  	  38	  
patients.  The study of CD will contribute to a greater understanding of TR expression in 
IBD because patients with CD can experience lesion pathology all throughout the 
gastrointestinal (GI) tract.  For instance, patients may experience lesions in one or many 
locations, i.e. the large bowel, the small bowel, the upper gastrointestinal tract, or a 
combination of these.  We will compare the TR phenotype of PBs in UC to those in CD 
patients that demonstrate only colon involvement.  We predict that this comparison will 
have either of two outcomes:  TR expression may be the same since the location of tissue 
involvement is identical in both circumstances, or different TRs may be involved in CD 
since the appearance of lesions is distinct from that in UC.  
 3.  Although not an IBD, we plan to investigate TR expression on PBs in celiac 
disease—a GI disorder characterized by localized inflammation/lesions in the small 
bowel due to gluten protein intolerance.  We will compare the TR phenotype of PBs in 
celiac disease to those in CD patients with small bowel involvement, again to determine 
if TR expression is the same if the location of tissue involvement is identical, or if 
different TRs are involved in the two diseases because the appearance of lesions is 
distinct.  
 Ultimately, through the comparison of TR expression on PBs in UC, CD, and 
celiac disease, we aim to develop (or would like to determine if it is possible to develop) 
a multicolor flow cytometry analysis of TRs that would enable us to distinguish between 
disease activity and location of pathology in these three inflammatory disorders. 
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